Gensight Biologics SA
Total Valuation
USDAs of December 31, 2024, GENSIGHT BIOLOGICS SA carries a market capitalization of 28.36M, placing it among publicly traded companies globally. Its enterprise value stands at 40.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 28.36M |
| Enterprise Value | 40.73M |
Important Dates
GENSIGHT BIOLOGICS SA's next confirmed earnings release is scheduled for March 19, 2027.
| Earnings Date | 3/19/2027 |
Share Statistics
As of December 31, 2024, GENSIGHT BIOLOGICS SA has 118.15M shares outstanding.
| Shares Outstanding | 118.15M |
Valuation Ratios
These figures are as of December 31, 2024.
| PB Ratio | -1.02 |
| P/TBV Ratio | -1.02 |
Financial Position
As of December 31, 2024, GENSIGHT BIOLOGICS SA maintains a current ratio of 0.24, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.24 |
| Quick Ratio | 0.11 |
| Debt / Equity | -53.54 |
Financial Efficiency
These figures cover the twelve months ended December 31, 2024.
| Employee Count | 14.00 |
Stock Price Statistics
USDAs of the close on October 1, 2026, GENSIGHT BIOLOGICS SA's stock has declined approximately 57.92% over the past 52 weeks.
| 52-Week Price Change | -57.92% |
| 50-Day Moving Average | 5.12 |
Balance Sheet
USDAs of December 31, 2024, GENSIGHT BIOLOGICS SA holds 2.55M in cash and equivalents against 14.92M in total debt, resulting in a net debt position of 11.24M. Total book value stands at -27.88M, with working capital of -17.89M providing operational flexibility.
| Cash & Cash Equivalents | 2.55M |
| Total Debt | 14.92M |
| Net Debt | 11.24M |
| Equity (Book Value) | -27.88M |
| Book Value Per Share | -0.24 |
| Working Capital | -17.89M |